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by interposition of a polytetrat1uoroethylene graft (Fig 2). 
Thereby, the en bloc resection of the tumor with the cervi-
cothoracic structures involved (eg, subclavian artery, first rib, 
lung) is safely achieved. In metastatic tumors, a single lung 
wedge resection can be sufficient to perform a radical opera-
tion; in primary lung cancer, an upper lobectomy with dis-
section limited to the upper mediastinal lymph nodes can also 
be performed through this approach and may be adequate for 
apical tumors.7 
Korst and Burt2 recently reported the largest series of resec-
tions of cervicothoracic tumors by the hemi-clamshell 
approach, clearly reviewing in the discussion the different 
techniques. They acknowledged that no single technique is 
without drawbacks and no agreement exists as to what con-
stitutes the optimal approach; however, in the conclusions 
they stated that the hem i-clamshell technique has significant 
advantages over the other approaches. 
In agreement with the authors, we prefer the hemi-
clamshell approach for resection of anterolateral tumors with 
chest and mediastinal invasion. However, those accustomed 
to the hemi-clamshell technique know how difficult it is to 
control and resect the subclavian artery through this 
approach, and Figs 2 and 3 in the article by Korst and Burt 
give an idea of such a problem. As a matter of fact, in that 
large series, no cases of subclavian artery resection were 
reported. 
The choice among the different approaches for apical chest 
tumor should be based on the tumor localization, as well as 
on the structures that have to be resected. When tumors are 
clearly located in the apical chest region invading the first rib 
and subclavian artery and crossing the border of the thoracic 
inlet to reach the cervical structures, we prefer the transma-
nubrial osteomuscular sparing approach. This technique may 
be combined with classic posterolateral thoracotomy or with 
anterolateral muscle sparing thoracotomy when extensive 
lymph node dissection and lung resection are required; finally 
a midline posterior approach should be used when hemiverte-
brectomy is required. 
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Reply to the Editor: 
We agree with Spaggiari and Pastorino that exposure of the 
subclavian artery for resection, although not commonly indi-
cated, plays an important role in the operative approach to 
apical chest tumors. However, we believe that the hemi-
clamshell approach provides adequate exposure to this vessel. 
To expose the subclavian artery adequately through a hemi-
clamshell incision, two maneuvers must be stressed. First, the 
incision and dissection must extend well up into the neck, 
similar to the cervical portion of the transmanubrial approach 
described by Spaggiari. This cervical dissection will expose 
the first several centimeters of the subclavian artery, well past 
the origin of the vertebral artery. Second, the anterior scalene 
muscle must be divided, which helps expose more length of 
the subclavian artery. The operative diagrams in our article l 
do not depict the division of this muscle because vascular 
resection was not indicated in that particular patient. These 
two components of the dissection allow the subclavian artery 
to be exposed adequately for resection when involved by 
tumor. 
Robert 1. Korst, MD 
Attending Surgeon 
Thoracic Service 
Memorial Sloan-Kettering Cancer Center 
1275 York Ave 
New York, NY 10021 
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Well-differentiated thymic carcinoma: Is it thymic 
carcinoma or not? 
To the Editor: 
We read the article titled "Thymic Carcinoma: Current 
Staging Does Not Predict Prognosis" by Blumberg and asso-
ciates of Sloan-Kettering Cancer Center (J Thorac 
Cardiovasc Surg 1998;115:303-9). Thymic carcinomas in this 
article consisted of type II malignant thymoma l and well-dif-
ferentiated thymic carcinoma.2 Our Nagoya City University 
series of thymic carcinoma consisted of 19 patients treated in 
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1980 through 1995. Inasmuch as there were 62 thymomas 
and 3 thymic carcinoids in the same period, the incidence of 
thymic carcinoma was 22.6% in thymic epithelial tumors. 
Because thymic carcinoma coincides with type II malignant 
thymoma according to our criteria, well-differentiated thymic 
carcinomas are excluded from our series. Histologic subtypes 
of our thymic carcinomas were as follows: squamous cell car-
cinoma, 11 cases; undifferentiated carcinoma, 3 cases; small 
cell carcinoma, 2 cases; lymphoepithelioma-like carcinoma, 
1 case; papillary adenocarcinoma, 1 case; and unclassified 
carcinoma, 1 case. Associated diseases were observed in 2 
patients: hypergammaglobulinemia in 1 patient and Cushing 
syndrome with hypogammaglobulinemia in another. 
Myasthenia gravis was not present. Applying the classifica-
tion of thymoma to our thymic carcinomas yields the follow-
ing stages: stage I, I case; stage II, 0 cases; stage III, 9 cases; 
stage IVa, 4 cases; and IVb, 5 cases. Follow-up results 
revealed a 42.7% 5-year survival and a 21.4% lO-year sur-
vival. The most important factor influencing survival was his-
tologic subtype. Five-year survival was 65.6% in squamous 
cell carcinoma and 14.3% in the other types of carcinoma. 
On comparing our results with those of the Sloan-Kettering 
series, we observed some differences. First, survivals in our 
series were inferior to those of Sloan-Kettering. Second, 
advanced stages of disease (stages III and IV) were prevalent 
in our series, as in that of Hsu and associates,3 which con-
sisted exclusively of type II malignant thymoma. Accord-
ingly, it is impossible to compare survivals of the patients 
with early and advanced stages of disease in our series. Third, 
none of our patients had associated myasthenia gravis. The 
explanation for these differences seems to be that our series 
excludes well-differentiated thymic carcinoma. 
We think that well-differentiated thymic carcinoma is dis-
tinct from type II malignant thymoma (proper thymic carci-
noma) because of differences of some markers (cytokeratins,4 
bcl-2, and Fas antigen5) and associated diseases. Well-differ-
entiated thymic carcinoma has been considered to be epithe-
lium-rich thymoma by most pathologists. It is related to cor-
tical thymoma (Miiller-Hermelink) or polygonal cell 
thymoma (Rosai) and frequently is associated with myasthe-
nia gravis. Designation of well-differentiated thymic carcino-
ma has caused striking confusion, because it overlaps with 
well-differentiated squamous cell carcinoma.6 The latter be-
longs to the category "proper thymic carcinoma" and consti-
tutes a low-grade category of thymic carcinoma, together 
with well-differentiated mucoepidermoid carcinoma and 
basaloid carcinoma. We agree with Suster and Moran's pro-
posal7 to designate well-differentiated thymic carcinoma as 
"atypical thymoma." Clinical results of "atypical thymoma," 
well-differentiated squamous cell carcinoma (low-grade), 
and other types of thymic carcinoma (high-grade) should be 
evaluated separately. Although the article by Blumberg and 
associates revealed no significant difference between sur-
vivals of patients with well-differentiated thymic carcinoma 
and type II malignant thymoma, we expect that an increase in 
the number of patients and longer observation times may 
reveal a difference. 
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Table I. TNM classification of thymic epithelial tumors 
T factor 
TI 
T2 
T3 
T4 
N factor 
NO 
NI 
N2 
N3 
M factor 
MO 
MI 
Macroscopically completely encapsulated and 
microscopically no capsular invasion 
Macroscopic adhesion or invasion into surrounding fatty 
tissue or mediastinal pleura, or microscopic invasion 
into capsule 
Invasion into neighboring organs, such as pericardium, 
great vessels, and lung 
Pleural or pericardial dissemination 
No lymph node metastasis 
Metastasis to anterior mediastinal lymph nodes 
Metastasis to intrathoracic lymph nodes except anterior 
mediastinal lymph nodes 
Metastasis to supraclavicular lymph nodes 
No hematogenous metastasis 
Hematogenous metastasis and/or extrathoracic lymph node 
metastasis except supraclavicular nodes 
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Patients with proper thymic carcinoma usually have an 
advanced stage of the disease. Accordingly, it seems almost 
meaningless to compare results of each stage in patients with 
proper thymic carcinoma. We think that the TNM classifica-
tion may be useful in thymic carcinomas. Table I shows the 
TNM classification system of thymic epithelial tumors, which 
is revised minimally from the one described in our previous 
article.8 T factors mimic the stages. N factors are arranged 
according to the lymph node stations along the lymphatic 
route from the thymus. TNM numbers of 5 cases of stage IVb 
in our series were as follows: T2 NI MO, T3 Nl MO, T3 NO 
MI, T3 N3 MI, and T4 NO M1. Three cases were N-positive 
and 3 cases were M-positive. However, evaluation of the N 
factor was not always complete, especially in the patients 
from the early period of our study. Therefore N-positive cases 
might be more frequent than our results indicate. As cases 
accumulate, this TNM classification system may become 
more useful. 
Akira Masaoka, MD 
Yosuke Yamakawa, MD 
Yoshitaka Fujii, MD 
Department of Surgery II 
Nagoya City University Medical School 
Nagoya, Japan 
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Reply to the Editor: 
My colleagues and I thank Masaoka and his associates for 
their letter and discussion. The authors point out one of the 
problems in dealing with tumors of the thymus: a variety of 
pathologic classifications have been devised, and the recent 
introduction of new classifications has caused a significant 
amount of confusion. A single classification of thymic tumors 
is greatly needed. 
We agree that well-differentiated thymic carcinoma is dif-
ferent from type II malignant thymoma. The point of our arti-
cle was that both of these malignant diseases can be aggres-
sive. We found that the tumors with the worst prognosis were 
those invading the innominate vein. Regardless of the patho-
logic diagnosis, fewer than 50% of patients treated for such 
tumors with complete resections will be disease-free at 5 
years, despite surviving. As Fig 1 in our original article 
demonstrates, even stage I and II thymic carcinoma will have 
a propensity to recur. In 10 years, 90% of thymic carcinomas 
of either type will recur, despite complete resection. 
We therefore concluded that either of these entities requires 
a much more aggressive management and might benefit from 
multimodality therapy. 
Robert J. Ginsberg, MD 
Department of Thoracic Surgery 
Memorial Sloan Kettering Cancer Center 
1275 York Ave 
New York City, NY 10021 
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Controlled cardiac reoxygenation in adults with 
ischemic heart disease 
To the Editor: 
We read with fascination the report by Kai Ihnken and 
associates I printed in the August 1998 issue of the Journal, in 
which standard, hyperoxic arterial POzs were compared with 
"normoxic" POzs during cardiopulmonary bypass (CPB) and 
found to cause measurable biochemical evidence of injury at 
the cellular level. We would like to ask several questions and 
to comment. Our questions relate to the initiation of anesthe-
sia in the patients who were subjected to normoxic CPB. The 
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common practice is for anesthesiologists to intubate and 
hyperoxygenate every patient, both during and after induc-
tion. Is this the way the patients in this group were handled? 
If so, could they not also have had an initial "reoxygenation" 
injury occurring at the time of anesthesia induction, if the POl 
of arterial blood was allowed to rise to extremely high levels 
before the initiation of CPB? Might the biochemical evidence 
of injury in the group subjected to hyperoxic bypass have 
been even more pronounced, by comparison, had prebypass 
POzs been controlled to physiologic levels upon intubation 
and induction of anesthesia in the other group of patients? 
Furthermore, might all of us be unintentionally contributing 
to injury of the heart in other clinical situations as well? 
We are in full agreement that the way in which oxygen is 
administered to adult patients with ischemic heart disease 
needs to be rethought. From our reading, it appears that this 
work represents a prolog to the introduction of "controlled 
cardiac reoxygenation," a concept borrowed from congenital 
heart surgery and used successfully in cyanotic children,z,3 
into another clinical area in which it may be applicable. This 
study suggests that, even in the adult patient with coronary 
heart disease and a "normoxic heart," considerable and cer-
tainly measurable cellular injury is occurring because of 
some of the known, toxic effects of high levels of molecular 
oxygen introduced abruptly into the coronary circulation. 
We would like to share our experience with the use of a 
strategy of controlled cardiac reoxygenation with 6 consecu-
tive patients taken to the operating room in the setting of 
advanced, evolving myocardial infarction. All were referred 
for emergency revascularization because catheter-based ther-
apies either were judged to be not feasible by the cardiologist 
or had failed to successfully interrupt the unstable syndrome. 
Half were in cardiogenic shock (pulmonary capillary wedge 
pressure> 18 mm Hg, cardiac index < 2.0 Llmin per square 
meter) at the time of entry to the operating room. All had 
multivessel coronary disease, profound diffuse myocardial 
contractile dysfunction (mean preoperative left ventricular 
ejection fraction was 28%), and had been having active 
symptoms for greater than 6 hours. Coexistent medical con-
ditions were what would be expected for such a patient pop-
ulation with a mean age of nearly 68 years. An average of 4 
bypass grafts was accomplished. In all 6 patients, deoxy-
genated blood cardioplegic solution was administered for ini-
tial warm induction and the POz of the reperfusate (initially 
35-45 mm Hg) was gradually raised over 20 minutes by alter-
ing the FIOZ of the membrane oxygenator and by changing the 
admixture of venous and arterial blood in the cardioplegia 
circuit. The pH of the initial cardioplegic solution, although 
from the venous side of the bypass circuit, was controlled in 
the normal range by adding bicarbonate or tromethamine as 
needed. The operations were completed with the use of inter-
mittent doses of cold (4°C) hyperoxygenated blood cardio-
plegic solution and a "hot shot" at the end of the crossclamp 
interval. In this group of patients, whom we expected to do 
relatively poorly on the basis of previous experience, we have 
had no deaths and the mean time to discharge from the hos-
pital was 8 days. The mean time to extubation for the group 
